NGAM Advisors L.P. increased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 15.1% during the second quarter, Holdings Channel reports. The fund owned 109,275 shares of the company’s stock after buying an additional 14,375 shares during the period. NGAM Advisors L.P.’s holdings in Myriad Genetics were worth $2,824,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Myriad Genetics during the first quarter valued at about $112,000. Creative Planning increased its position in shares of Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock valued at $122,000 after buying an additional 671 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Myriad Genetics during the first quarter valued at about $144,000. Karp Capital Management Corp acquired a new position in shares of Myriad Genetics during the first quarter valued at about $223,000. Finally, Parametrica Management Ltd acquired a new position in shares of Myriad Genetics during the first quarter valued at about $236,000.
Myriad Genetics, Inc. (NASDAQ:MYGN) opened at 27.20 on Friday. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $28.39. The firm’s 50-day moving average is $25.14 and its 200 day moving average is $20.84. The stock has a market capitalization of $1.86 billion, a PE ratio of 85.27 and a beta of 0.31.
Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.36 earnings per share. On average, equities analysts forecast that Myriad Genetics, Inc. will post $1.05 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “NGAM Advisors L.P. Increases Position in Myriad Genetics, Inc. (MYGN)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/2801579/ngam-advisors-l-p-increases-position-in-myriad-genetics-inc-mygn.html.
Several brokerages have recently issued reports on MYGN. Jefferies Group LLC reiterated a “hold” rating and set a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a research report on Thursday. BidaskClub cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Barclays PLC dropped their target price on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Wednesday. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Monday, July 17th. Finally, Cowen and Company reissued a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a report on Friday, July 14th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics presently has an average rating of “Hold” and an average price target of $21.78.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.